Thornton and Ross Ltd

Recent awards

• NHS National Generic Pharmaceuticals - Wave 16a
  27 August 2026 · £393,331,872
• NHS National Generic Pharmaceuticals - Wave 16a
  27 August 2026 · £21,026,178
• NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
  15 June 2026 · £166,347,397
• NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
  15 June 2026 · £665,389,588
• Ustekinumab
  4 June 2026 · £6,532,463
• NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
  1 June 2026 · £813,863,584
• NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
  1 June 2026 · £18,903,212
• NHS National Branded Interim - 1 June 2026
  10 April 2026 · £529,090,780
• NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide
  24 March 2026 · £19,595,208
• Transitional Drugs 6
  29 January 2026 · £1,637,728